One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x10 12 /l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.

Introduction:Belching is often reported symptom. It is rarely an isolated disorder and mainly occurs within various gastroduodenal diseases.Aim:The aim is to show the great breadth of clinical symptoms of postcholecystectomy syndrome which should have a multidisciplinary therapeutic approach taking into account all aspects of patient’s life.Case report:We report a case of excessive belching within postcholecystectomy syndrome which disturbs the general psycho-physical condition of the patient, with symptoms of depression and anxiety, and social isolation, which significantly reduces the quality of his life.

One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x10 12/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.

One of the most common associated diseases in dialysis patients is anemia. The number of erythrocytes, hemoglobin and hematocrit is reduced in patients that suffer from anemia. These three measurement parameters represent the most important "red part" of the blood count. Due to renal insufficiency, patients on hemodialysis do not have enough erythropoietin, which healthy kidneys excreted, and is necessary for hematopoiesis. Erythropoietin (EPO) is the main regulator of the daily production of red blood cells. EPO that is execrated by peritubular capillary membrane cells in the kidneys circulates within plasma in order to interact with target cells in the bone marrow to maintain or stimulate erythropoiesis. The main purpose of the action of EPO is the formation of erythroid colonies. During observation of differences in the ordination of EPO in each group between men and women, there is no statistical significance evident in the incidence of anemia before and after therapy, as in p=0.70. The target concentration of hemoglobin, which must be constantly maintained in people with chronic renal anemia, is 110-120 g/l, while the target value of the number of red blood cells is 4-5x10 12/l and the hematocrit value is 0.35-4.5 l/l, with a slight outflow depending on the gender of the patient. The final values of the participants in our study treated with epoetin alpha show higher values of hemoglobin, hematocrit and erythrocytes, while the average values recorded in participants treated with darbepoetin decreased.